<DOC>
	<DOCNO>NCT02131220</DOCNO>
	<brief_summary>The purpose study determine whether intracoronary selective thrombolysis effective tirofiban coronary flow primary percutaneous coronary intervention acute myocardial infarction .</brief_summary>
	<brief_title>Effects Intracoronary Prourokinase Coronary Flow During Primary Percutaneous Coronary Intervention Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Saruplase</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<criteria>STsegment elevation AMI within 12 hour symptom onset Contraindications thrombolysis PCI Patients administer fibrinolytic agent PCI Patients enrol clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>No-Reflow Phenomenon</keyword>
</DOC>